No Evidence for Posttreatment Effects of Vitamin D and Calcium Supplementation on Risk of Colorectal Adenomas in a Randomized Trial
Cancer Prevention Research DOI: 10.1158/1940-6207.CAPR-19-0023
Audrey H. Calderwood, John A. Baron, Leila A. Mott, Dennis J. Ahnen, Roberd M. Bostick, Jane C. Figueiredo, Michael N. Passarelli, Judy R. Rees, Douglas J. Robertson and Elizabeth L. Barry
That they used only a paltry 1,000 IU was hidden deep inside of the PDF
- "Following eligibility screening and a 56-84 day placebo run-in period, 2259 participants were randomly assigned in a partial 2 x 2 factorial design to receive vitamin D3 (1000 IU/day), calcium carbonate (1200 mg elemental calcium/day), both agents, or placebo only (full factorial randomization). "
- A few diseases are PREVENTED by 1,000 IU of vitamin D, but I cannot recall any which are TREATED by that small of a dose. Founder of VitaminDWiki April 2019
- Advanced Colorectal Cancer survival is increased somewhat with 4,000 IU of vitamin D – RCT April 2019
- Colon cancer patients with high vitamin D live 1 year longer – June 2015
- Colon cancer – how vitamin D prevents and treats it – Nov 2014
- Overview Cancer-Colon and vitamin D
- Colorectal Cancer recurrence not prevented by 1,000 IU of vitamin D – meta-analysis Dec 2016
No such attachment on this page
Vitamin D and calcium supplementation are postulated to have chemopreventive effects against colorectal neoplasia, yet in our previously reported randomized trial, there was no overall efficacy of calcium and/or vitamin D3 against colorectal adenoma recurrence. It is possible vitamin D3 and calcium chemopreventive effects are not detectable until beyond the 3- to 5-year follow-up captured in that trial. Accordingly, we explored possible vitamin D and calcium effects on posttreatment (observational) adenoma occurrence. In this secondary analysis of the observational follow-up phase of the Vitamin D/Calcium Polyp Prevention Study, participants who completed the treatment phase were invited to be followed for one additional surveillance colonoscopy cycle. We evaluated adenoma occurrence risk at surveillance colonoscopy, with a mean of 55 ± 15 months after treatment follow-up, according to randomized treatment with vitamin D versus no vitamin D, calcium versus no calcium, and calcium plus vitamin D versus calcium alone. Secondary outcomes included advanced and multiple adenomas. Among the 1,121 participants with observational follow-up, the relative risk (95% confidence interval, CI) of any adenoma was 1.04 (0.93–1.17) for vitamin D versus no vitamin D; 0.95 (0.84–1.08) for calcium versus no calcium; 1.07 (0.91–1.25) for calcium plus vitamin D versus calcium; and 0.96 (0.81–1.15) for calcium plus vitamin D versus neither. Risks of advanced or multiple adenomas also did not differ by treatment. Our results do not support an association between supplemental calcium and/or vitamin D3 for 3 to 5 years and risk of recurrent colorectal adenoma at an average of 4.6 years after treatment.